Neuroptix Corporation


Press Releases

September 13, 2006

Neuroptix Announces Breakthrough Preclinical Tests of QEL™ Platform for Non-Invasive Early Detection of Alzheimer’s

Acton, Massachusetts – September 13, 2006 – Neuroptix Corporation, a Massachusetts-based Alzheimer’s diagnostics company, today announced that recent tests of its QEL™ diagnostic platform on mice demonstrated that the optical scanning system was able to detect amyloid protein aggregates in the lens of the eye prior to toxic plaque build-up in the brain.

“We are very excited and encouraged by the results of recent testing of the QEL™ system,” said Paul Hartung, President and CEO of Neuroptix. “We are confident that further experimentation and development of our scanning technology will help bring non-invasive, reliable and inexpensive predictive diagnostics for Alzheimer’s closer to clinical use.”

The results of the tests, performed by Dr. Lee Goldstein of Brigham and Women’s Hospital in Boston, and his team, were recently announced at the International Conference on Alzheimer's Disease and Related Disorders in Spain. Dr. Goldstein’s team utilized the QEL™ system to scan the eyes of genetically-engineered mice with Alzheimer’s with a low-power pulse of infrared light, in search of the same beta amyloid lesions that would also indicate the presence the protein’s signature plaques in the brains of Alzheimer’s patients. The team discovered that over the course of several months, the QEL™ system was sensitive enough to be able to both detect and monitor progression of the beta amyloid proteins in Alzheimer’s mice.

The QEL™ system combines laser-based technologies – quasi-elastic light scattering (QLS) and fluorescent ligand scanning (FLS) – to examine and measure deposits in specific areas of the eye.

The next stage of development for the technology is the creation of instruments for clinical trials, and the safety testing of the fluorescent ligands for human use.

About Neuroptix Corporation

Founded in 2001, Neuroptix develops, manufactures and distributes state-of-the-art products for extremely sensitive measurements of biophysical changes in the eye, including a non-invasive instrument (QEL 2400) for diagnosis and monitoring Alzheimer's disease that is now undergoing clinical study. Adaptable and innovative, Neuroptix’s products are designed for a variety of research environments including academic and pharmaceutical laboratories.  Neuroptix is also developing imaging compounds for application in screening tests for Alzheimer’s disease and prion diseases.

For more information, contact or visit the web site at


#  #  #